MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government_Funders & Regulators
*Government: International
Europe
*Europe: Regions
*Western Europe
Switzerland
*Industry: Switzerland
Mind-NRG, SA
Parents
*Architects: Biotechnology_Peptides
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars)
*Industry: Switzerland
Index Ventures
Venture Capital: Series A
Children
10 Jan 2011 Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing.
Claims it has disease-modifying potential and can cross the blood-brain barrier by receptor-mediated transport to reach its targ
Index Pledges €10M to New Company’s Development of Peptide Candidates for CNS Diseases (2010)
Index Ventures has pledged to provide up to a €10 million (about $14 million) investment in Mind-NRG
Newly incorporated Swiss CNS disease therapeutics firm (2010).
Participants include Index Ventures.
The new company is focused on the development of a peptidic neurotrophic factor candidate NRG-101